Regeneron Pharmaceuticals Inc.

History

Year	Detail
1988	Regeneron was founded.
1990	Announced a collaboration to develop neurotrophic factors.
1992	Clinical development of investigational drug, a neurotrophic factor, begins.
2000	Investigational medicine rilonacept begins clinical exploration.
2004	Investigational medicine aflibercept begins clinical development.
2006	Entered a collaboration with Bayer HealthCare.
2007	The company collaborated with Sanofi.
2008	The FDA approved first medicine, ARCALYST Injection.
2013	European business office opens in Dublin, Ireland.
2015	Launched a major new immuno-oncology collaboration with Sanofi.
2022	The company acquried Checkmate Pharmaceuticals.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.